<DOC>
	<DOCNO>NCT02229812</DOCNO>
	<brief_summary>Study evaluate safety efficacy intravenous alteplase within 3 hour symptom onset acute ischemic stroke patient</brief_summary>
	<brief_title>Safe Implementation Thrombolysis Stroke - Monitoring Study</brief_title>
	<detailed_description />
	<mesh_term>Stroke</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>Female male inpatient Age 18 80 year Clinical diagnosis ischemic stroke cause measurable neurological deficit define impairment language , motor function , cognition , gaze , vision and/or neglect . Ischemic stroke defined event characterize sudden onset acute focal neurological deficit , presume caused cerebral ischemia , CT scan exclusion hemorrhage Onset symptom within 3 hour prior initiation thrombolysis treatment Stroke symptom present least 30 minute significantly improve treatment . Symptoms must distinguishable episode generalize ischemia ( i.e . syncope ) , seizure , migraine disorder Patients willing receive thrombolysis treatment give inform consent regard retrieval data follow procedure , accord regulation participate country Willingness ability comply study protocol Evidence intracranial hemorrhage ( ICH ) CTscan Symptoms ischemic attack begin 3 hour prior infusion start time symptom onset unknown Minor neurological deficit symptom rapidly improve start infusion Severe stroke assess clinically and/or appropriate imaging technique Seizure onset stroke Symptoms suggestive subarachnoid hemorrhage , even CTscan normal Administration heparin within previous 48 hour thromboplastin time exceed upper limit normal laboratory Patients history prior stroke concomitant diabetes Prior stroke within last 3 month Platelet count 100,000/mm³ Systolic blood pressure &gt; 185 mmHg diastolic blood pressure &gt; 110 mmHg , aggressive management ( IV medication ) necessary reduce BP limit Blood glucose &lt; 50 &gt; 400 mg/dl Known hemorrhagic diathesis Patients receive oral anticoagulant , e.g . warfarin sodium Manifest recent severe dangerous bleed Known history suspect intracranial hemorrhage Suspected subarachnoid hemorrhage condition subarachnoid hemorrhage aneurysm Any history central nervous system damage ( i.e . neoplasm , aneurysm , intracranial spinal surgery ) Hemorrhagic retinopathy , e.g . diabetes ( vision disturbance may indicate hemorrhagic retinopathy ) Recent ( less 10 day ) traumatic external heart massage , obstetrical delivery , recent puncture noncompressible bloodvessel ( e.g . subclavian jugular vein puncture Bacterial endocarditis , pericarditis Acute pancreatitis Documented ulcerative gastrointestinal disease last 3 month , oesophageal varix , arterial aneurysm , arterial/venous malformation Neoplasm increase bleed risk Severe liver disease , include hepatic failure , cirrhosis , portal hypertension oesophageal varix ) active hepatitis Major surgery significant trauma past 3 month All exclusion criterion follow summary product characteristic Actilyse®</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>